David Hayes
Analyst, Jefferies
Replay available
Beiersdorf Ag (OTC: BDRFF) Q4 2025 earnings conference call, held 2026-03-03. Replay captured from the company's public earnings webcast.

Analyst, Jefferies
Analyst, HSBC
Analyst, BNP Paribas
Analyst, Goldman Sachs
Analyst, Bernstein
Analyst, RBC Capital Markets
Analyst, JP Morgan
Reporter, Reuters
Analyst, UBS
Analyst, Kepler Cheuvreux
Analyst, Bank of America
Analyst, Barclays
Good morning everyone and thank you for joining us for our full year 2025 results conference. I'm pleased to present an overview of our performance together with Astrid, who will later provide a detailed financial review. But before we begin, I want to touch on the situation in the Middle East. In situations like these, the safety of our employees and their families is our highest priority. Teams are in place in the regions to offer assistance and support on the ground, and we are in close communication with them. Given the volatility of the situation, it is too early to assess any potential impact on our business. We hope for a peaceful solution soon. Let me now turn to our full-year 2025 results. 2025 was a year that demanded a lot from us. Economic and geopolitical uncertainties, shifting consumer behavior, and continued trade disruptions negatively affected market dynamics. Skincare market growth slowed to levels not seen in recent history, with particularly strong effects in the emerging markets region. These conditions shaped and challenged our performance more than anticipated at the start of the year. Even though we continued to make progress in several important areas, and where we fell short, we took immediate action. At the same time, 2025 showed that the core elements of our strategy remain effective, our focus on science-based innovation, our global footprint and expansion into new markets, our culture of care and responsibility. This provided important stability throughout the year. In the challenging market environment, we were able to maintain our position as the best performing skincare company globally for the third year in a row. Once again, our derma business was a disputed success, driven by innovation, wide space expansion, and strong scientific...